Cryoport Inc (CYRX) - Total Liabilities
Based on the latest financial reports, Cryoport Inc (CYRX) has total liabilities worth $265.50 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CYRX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Cryoport Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Cryoport Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CYRX current and non-current assets.
Cryoport Inc Competitors by Total Liabilities
The table below lists competitors of Cryoport Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
China | CN¥658.60 Million |
|
Amtran Technology Co Ltd
TW:2489
|
Taiwan | NT$9.00 Billion |
|
Beta Bionics, Inc. Common Stock
NASDAQ:BBNX
|
USA | $36.02 Million |
|
LIGHTHOUSE PROPERTIES
F:87O
|
Germany | €738.44 Million |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.37 Billion |
|
Thanh Thanh Cong Tay Ninh JSC
VN:SBT
|
Vietnam | ₫26.26 Trillion |
|
Northern Dynasty Minerals Ltd
TO:NDM
|
Canada | CA$66.90 Million |
|
Renta 4 Banco S.A
MC:R4
|
Spain | €2.43 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Cryoport Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Cryoport Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cryoport Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cryoport Inc (2004–2025)
The table below shows the annual total liabilities of Cryoport Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $262.35 Million | -13.01% |
| 2024-12-31 | $301.59 Million | -35.66% |
| 2023-12-31 | $468.72 Million | -2.94% |
| 2022-12-31 | $482.91 Million | +2.50% |
| 2021-12-31 | $471.14 Million | +177.62% |
| 2020-12-31 | $169.71 Million | +1669.26% |
| 2019-12-31 | $9.59 Million | -46.93% |
| 2018-12-31 | $18.07 Million | +660.24% |
| 2017-12-31 | $2.38 Million | -2.23% |
| 2016-12-31 | $2.43 Million | -1.49% |
| 2015-12-31 | $2.47 Million | -18.35% |
| 2014-12-31 | $3.02 Million | -24.70% |
| 2013-12-31 | $4.01 Million | +5.12% |
| 2012-12-31 | $3.82 Million | +53.74% |
| 2011-12-31 | $2.48 Million | -51.13% |
| 2010-12-31 | $5.08 Million | -10.68% |
| 2009-12-31 | $5.69 Million | -3.50% |
| 2008-12-31 | $5.90 Million | +112.79% |
| 2007-12-31 | $2.77 Million | +18.25% |
| 2006-12-31 | $2.34 Million | -4.08% |
| 2005-12-31 | $2.44 Million | +8.10% |
| 2004-12-31 | $2.26 Million | -- |
About Cryoport Inc
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic … Read more